Article Text

Download PDFPDF
Proliferating cell nuclear antigen (PCNA) immunoreactivity in ovarian serous and mucinous neoplasms: diagnostic and prognostic value
  1. N. Wilkinson,
  2. C. H. Buckley,
  3. H. Fox,
  4. R. J. Hale,
  5. L. Chawner and
  6. Li-Na Guo*
  1. Department of Reproductive Pathology, St. Mary's Hospital, Manchester and Department of Pathological Sciences, University of Manchester, UK
  2. * Peking Union Medical College, Beijing, China
  1. Address for correspondence: Professor H. Fox, Department of Pathological Sciences, Stopford Building, University of Manchester, Oxford Road, M13 9PT, UK.


Sixty-two serous and mucinous ovarian tumors, an admixture of benign, borderline and malignant neoplasms, were immunostained for proliferating cell nuclear antigen (PCNA), with the monoclonal antibody PC10. The PC10 index, the proportion of cells showing nuclear positive staining, was calculated in each case. All the tumors showed positive immunoreactivity for PCNA. There was no overlap of PC10 counts between benign, borderline and malignant serous tumors but within the mucinous group of neoplasms there was considerable overlap between the counts for borderline and malignant tumors. There was no relationship between the PC10 index and the surgical stage of the malignant neoplasms and the index could not be correlated with patient death. Staining for PCNA does not, therefore, appear to be of any prognostic value in ovarian adenocarcinomas.

  • PCNA in ovarian neoplasms.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.